Quarterly updateAkari Therapeutics PlcAtrium TherapeuticsBeyondSpring Pharmaceuticals Inc.Eikon reports Q3 2026 results, ESMO oncology data and new prostate cancer INDEikon Therapeutics disclosed updated lung cancer data, a registrational trial start, and an IND filing for a new prostate cancer drug, alongside $461.7 million in cash.SEC filing (12)
Quarterly updateWhitehawk Therapeutics, Inc.Whitehawk reports Q3 2026 results, starts Phase 1 trial of HWK-206 with Fast Track tagThe company began dosing in a new Phase 1 study of its third ADC candidate and said cash on hand should fund operations into the second half of 2028.SEC filing
PeopleWhitehawk Therapeutics, Inc.Whitehawk Therapeutics adds Vijay Iyengar to board of directorsThe clinical-stage oncology company named the former Incyte executive as a Class III director effective September 9, 2026.SEC filing